Opinion

Video

AGAVE-201 Investigating Axatilimab In Recurrent of Refractory cGVHD

Author(s):

Hannah Choe, MD

Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.

Related Videos
Justin Kaner, MD
Minoo Battiwalla, MD, MS, director, Blood Cancer Outcomes Research, Sarah Cannon Research Institute, TriStar Medical Group
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Shyam A. Patel, MD, PhD
Amitkumar Mehta, MD
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Jean L. Koff, MD, MS
Related Content
Jorge Cortes, MD
October 17th 2024

Asciminib Yields Promising Efficacy vs SOC Agents in CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
October 16th 2024

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

Alice Mims, MD, medical oncologist, associate professor, the Division of Hematology, The Ohio State University Comprehensive Cancer Center—James
February 26th 2024

Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

Armin Ghobadi, MD, of the Washington University School of Medicine
October 7th 2024

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

Helen Collins, MD, Enliven Therapeutics
October 7th 2024

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML